The Sensorion CEO transition marks a significant leadership update for Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company developing innovative therapies for hearing loss disorders. The company confirmed that Nawal Ouzren has stepped down as Chief Executive Officer and Board Director, effective immediately. Amit Munshi, Chairman of the Board, has assumed the role of Interim Chief Executive Officer.
Ouzren stepped down due to a personal matter. However, she will remain temporarily as a consultant to ensure a smooth and structured transition. Meanwhile, the Board has initiated a search for a permanent CEO to guide the company’s next phase of growth.
Leadership Change at a Strategic Milestone
The executive transition comes at an important moment for Sensorion. Since 2017, Ouzren strengthened the company’s clinical pipeline and corporate strategy. As a result, Sensorion now operates from a solid financial and operational foundation.
Recently, the company secured a €60 million private placement led by Sanofi, alongside leading healthcare institutional investors. This financing strengthens the balance sheet and extends the company’s cash runway through the end of H1 2027. Therefore, the leadership change occurs while business momentum remains strong.
Interim Leadership and Strategic Continuity
Amit Munshi will oversee operations during the transition period. He thanked Ouzren for her contributions and reaffirmed the company’s commitment to advancing its development programs. In addition, he emphasized maintaining clinical timelines and corporate growth objectives.
The management team continues to execute its strategic roadmap. Consequently, the company does not expect disruptions to its research or development plans.
Focus on Advancing Gene Therapy Pipeline
Sensorion plans to allocate most of the recent financing to accelerate its next-generation gene therapy programs. These therapies target genetic causes of hearing loss that affect millions worldwide.
Key programs include:
SENS-601 (GJB2-GT)
This gene therapy candidate targets hearing loss associated with GJB2 mutations. These mutations account for approximately 50% of autosomal recessive non-syndromic congenital hearing loss. The company expects to submit its clinical trial application in Q1 2026.
SENS-501
This therapy is currently under evaluation in the Phase 1/2 Audiogene trial. It targets hearing loss related to GJB2 gene mutations. Importantly, six-month follow-up data from cohort two is anticipated in Q1 2026.
Outlook for Investors and Stakeholders
Although leadership transitions can create uncertainty, Sensorion maintains strong financial backing and clear development priorities. Moreover, the company continues to pursue key clinical milestones and long-term growth objectives.
Overall, the Sensorion CEO transition reflects governance continuity and strategic stability. With interim leadership in place and funding secured, Sensorion remains focused on delivering innovative therapies for patients affected by genetic hearing loss disorders.
Read Also: Worldwide Clinical Trials Completes Catalyst Acquisition
